Maximizing Efficiency and Flexibility in Viral Vector Manufacturing Scale-up
March 02, 2023
Denis Kole, Jon Petrone, Marc Bisschops and Nathan Hazi
Four viral vector experts from diverse groups within Pall Corporation’s gene therapy manufacturing organization – Denis Kole, Jon Petrone, Marc Bisschops and Nathan Hazi – join BioInsights to share insights in hot topics for the field, including optimizing upstream process yield and titer, full/empty/partially full capsid separation, and platform process development.
Key current challenges in viral vector processing
Technological advancements in upstream processing
Ensuring optimal consistency through scale-up/out
What’s next for transient transfection?
Enabling viral vector process intensification
How well are the current range of purification technologies performing?
How best to improve full/empty/partially full capsid ratio?
Standardized vector platform processes
Minimum process parameters needed to build a platform viral vector process
Automating gene therapy manufacture for rare disease indications